1Laml T, Schulz- Lobmeyr I, Obruca A, et al. Premature ovarian failure:etiology and prospects. Gynecol Endocrinol,2000 Aug, 14:292-302.
2Kim TJ, Anasti JN, Flack MR, et al. Routine endocrine acreening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol, 1997,89:777-779.
3Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinology and Metabolism Clinics of North America, 1998,27:989-1006.
4Nelson LM, Anasti .IN, Kimaey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab, 1994,79:1470-1475.
5Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol, 1998,91 : 12-15.
6Novosad JA, Kalantaridou SN, Tong ZB, et al. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health,2003,3: 2.
7Van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum-Reprod-Update, 1999 Sep-Oct,5(5) : 483-492.
8Arici A, Matalliotakis IM, Koumantakis GE et al. Diagnostic role of inhibin B in resistant ovary syndrome associated with secondary amenorrhea. Fertil Steril,2002, 78(6): 1324-6.
